Products

Rituximab (TP-082CL)

rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids      

Specifications
Classify
Protein therapeutics that interfere with a molecule or organism: Cancer
Therapeutic
Rituximab
Trade Name
rituximab
Function
Chimeric (human/mouse) mAb that binds cD20, a transmembrane protein found on over 90% of B-cell non-Hodgkin's lymphomas (NHL); synergistic effect with some small-molecule chemotherapeutic agents has been demonstrated in lymphoma cell lines
Examples of Clinical Use
Relapsed or refractory low-grade or follicular cD20+ B-cell NHL, primary low-grade or follicular cD20+ B-cell NHL in combination with cvP chemotherapy; diffuse large B-cell cD20+ NHL in combination with cHOP or other anthracyline- based chemotherapy; rheumatoid arthritis in combination with methotrexate
References
Synonyms
AntiCD20, Ig gamma-1 chain C region
UniProt
P01857
Genbank
J00228

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
Name:
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Please input "biolabs"(case insensitive) as verification code.
Contact Us to Order
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email:

45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-871-5806    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2017 Creative-Biolabs All Rights Reserved